Merck’s RSV drug meets key end-stage trial targets
Merck said Tuesday that its respiratory syncytial virus (RSV) drug met safety and efficacy targets in a mid- to late-stage study testing it in infants.
POPULAR POSTS
Pope Francis calls for action on climate change
September 6, 2024
Climate change costing Africa up to 5% of GDP, UN says
September 6, 2024
A forest fire has destroyed 20% of the forests in Brazil
September 6, 2024
Toronto Film Festival showcases an industry transformed by streaming
September 6, 2024
LIVE STREAM
